NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) “Relapsed/Refractory Multiple Myeloma”
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:April 14, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:April 14, 2022Completed
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 8, 2022Completed
Condition(s):Relapsed and Refractory Multiple Myeloma (RRMM)Last Updated:February 8, 2023Active, not recruiting
Condition(s):Refractory Multiple Myeloma; Relapsed Multiple MyelomaLast Updated:January 10, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 31, 2022Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:January 8, 2021Terminated
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 9, 2022Active, not recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:December 1, 2022Active, not recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 15, 2023Active, not recruiting
Condition(s):Relapse/Refractory Multiple MyelomaLast Updated:November 18, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.